Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
8.66
-0.72 (-7.68%)
At close: Dec 5, 2025, 4:00 PM EST
8.83
+0.17 (1.96%)
After-hours: Dec 5, 2025, 7:42 PM EST
Sutro Biopharma Stock Forecast
Stock Price Forecast
According to 6 professional analysts, the 12-month price target for Sutro Biopharma stock ranges from a low of $8.00 to a high of $30. The average analyst price target of $19.67 forecasts a 127.14% increase in the stock price over the next year.
Price Target: $19.67 (+127.14%)
Analyst Consensus: Hold
* Price targets were last updated on Aug 12, 2025.
Analyst Ratings
The average analyst rating for Sutro Biopharma stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 4 | 5 | 5 | 5 | 5 | 5 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold Maintains $40 → $30 | Hold | Maintains | $40 → $30 | +246.42% | Aug 12, 2025 |
| Piper Sandler | Piper Sandler | Hold → Buy Upgrades $20 | Hold → Buy | Upgrades | $20 | +130.95% | Jun 16, 2025 |
| B of A Securities | B of A Securities | Sell Maintains $10 → $8 | Sell | Maintains | $10 → $8 | -7.62% | May 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $20 | Hold | Reiterates | $20 | +130.95% | Apr 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $120 → $20 | Strong Buy → Hold | Downgrades | $120 → $20 | +130.95% | Mar 17, 2025 |
Financial Forecast
Revenue This Year
100.89M
from 62.04M
Increased by 62.61%
Revenue Next Year
46.45M
from 100.89M
Decreased by -53.96%
EPS This Year
-2.15
from -29.61
EPS Next Year
-1.32
from -2.15
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 115.5M | 98.6M | ||||
| Avg | 100.9M | 46.5M | ||||
| Low | 89.0M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 86.2% | -2.3% | ||||
| Avg | 62.6% | -54.0% | ||||
| Low | 43.5% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.97 | -0.63 | ||||
| Avg | -2.15 | -1.32 | ||||
| Low | -2.16 | -1.91 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.